<DOC>
	<DOCNO>NCT02893865</DOCNO>
	<brief_summary>Published data indicate obstructive sleep apnea syndrome ( OSAS ) bad prognosis coronary artery disease ( CAD ) oxidative stress link 2 disease . Investigators hypothesise oxidative stress decrease 3 month continuous positive airway pressure ( CPAP ) specific population . The result may major implication comprehension physiopathologic process link OSAS CAD treatment OSAS specific population .</brief_summary>
	<brief_title>Evolution Oxidative Stress Coronary Patients With Moderate Sleep Apnea Syndrome After Treatment With Continuous Positive Airway Pressure</brief_title>
	<detailed_description>Obstructive sleep apnea syndrome ( OSAS ) common disorder characterize recurrent upper airway collapse sleep associate worsened prognosis patient coronary artery disease ( CAD ) . Moderate OSAS define apnea hypopnea index ( AHI ) 15 30 events/hour . Pathophysiologic process complex seem oxidative stress play important role . Studies show continuous positive airway pressure ( CPAP ) influence oxidative stress result conflict . Moreover uncertainties whether diagnose treat OSAS inﬂuence pathophysiological clinical outcome patient CAD . Therefore , aim test effect 3 month CPAP systemic redox balance evaluate plasma GSH/GSSG ratio . Patients moderate OSAS randomize intervention . Patients AHI &lt; 15/h &gt; 30/h include ancillary study ( blood urinary test , MIBG scintigraphy ) characterize biological profile coronary patient base AHI . For alpha threshold 5 % study power 80 % , study include 16 patient group . Taking account possible 20 % dropout study need include 20 patient randomized arm demonstrate effect .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<criteria>Apnea Hypopnea Index 1530/h Stable Coronary artery disease Obligation obtain informed consent form Heart failure LVEF le equal 45 % Other Chronic disease : renal failure , COPD Index central apnea equal 50 % total IAH treatment CPAP mandibular advancement device IMC &gt; 40 kg / m² Nutritional supplementation 4 week precede study ( antioxidant , vitamin ... ) . Treatment allopurinol Nacetylcysteine , 4 week precede study . PaCO2 &gt; 45 mmHg Counterindication use PPC : bullous lung disease , pathological hypotension , bypass airway , pneumothorax , sign sinus infection inner ear Exclusion period subject compare another protocol maximum annual amount compensation € 4,500 reach . Participation subject another study . Not affiliated social security scheme subject beneficiary regime . Pregnant breastfeed woman , patient unable give consent , protect adult , vulnerable Subject deprive liberty judicial administrative decision HIV infection , hepatitis B hepatitis C known</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Apnea syndrome</keyword>
	<keyword>Coronary artery disease</keyword>
	<keyword>Oxidative stress</keyword>
	<keyword>Continuous positive airway pressure</keyword>
	<keyword>Endothelial dysfunction</keyword>
</DOC>